CFHR1与CFHR3缺失变异与IgA肾病系膜免疫沉积相关但不影响进展
该回顾性单中心队列纳入639例白人活检证实的IgA肾病患者,按CFHR3,1Δ基因型比较肾脏结局。结果发现CFHR3,1Δ与诊断时年龄、eGFR、尿蛋白、高血压或血尿无关,且不 association 进展至CKD 3期或肾脏死亡,但与较低的IgA、IgG和C3系膜免疫沉积强度相关。
要点
- CFHR3,1Δ与IgA肾病患者诊断时临床指标无关。
- CFHR3,1Δ与较低的系膜免疫沉积强度相关。
- CFHR3,1Δ不 association 进展至CKD 3期或肾脏死亡。
核心结论
- 在白人IgA肾病人群中,CFHR3,1Δ基因型与进展至CKD 3期和5期无关,但与肾小球免疫沉积水平降低有关。
研究设计与样本
- 回顾性单中心队列研究纳入639例自1979年以来活检证实的白人IgA肾病患者,诊断时平均年龄40.1岁,中位随访132个月。
- 通过定量PCR确定CFHR3和CFHR1基因拷贝数,并回顾病历收集临床和生物学数据。
主要发现
- 30.5%的患者为CFHR3,1Δ杂合子,4%为纯合子。
- CFHR3,1Δ与诊断时年龄、eGFR、尿蛋白排泄率、高血压或血尿的存在无关。
- 杂合或纯合基因缺失组的免疫IgA、IgG和C3沉积平均强度低于无缺失组。
- CFHR3,1Δ与进展至CKD 3期或肾脏死亡无关。
临床怎么用
- CFHR3,1Δ检测可能有助于理解IgA肾病免疫沉积机制,但当前不推荐用于预测肾脏进展风险。
局限性
- 回顾性单中心设计,仅纳入白人患者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Activation of complement through the alternative pathway has a key role in the pathogenesis of IgA nephropathy (IgAN). Large, international, genome-wide association studies have shown that deletion of complement factor H-related genes 1 and 3 (CFHR3,1Δ) is associated with a reduced risk of developing IgAN, although the prognostic value of these deletions in IgAN remains unknown. Here, we compared the renal outcomes of patients with IgAN according to their CFHR3,1Δ genotype. This retrospective, monocentric cohort study included 639 white patients with biopsy-proven IgAN since 1979 (mean age at diagnosis, 40.1 years; median follow-up, 132 months). We determined the number of CFHR3 and CFHR1 gene copies by quantitative PCR and collected clinical and biologic data by reviewing the patients' medical records. In all, 30.5% of the patients were heterozygous and 4% were homozygous for CFHR3,1Δ We did not detect an association between CFHR3,1Δ and age, eGFR, urinary protein excretion rate, or the presence of hypertension or hematuria at the time of diagnosis. The mean intensities of immune IgA, IgG, and C3 deposits were lower in the group with heterozygous or homozygous gene deletions than in those with no deletion. However, CFHR3,1Δ did not associate with progression to stage 3 CKD or renal death. In conclusion, the CFHR3,1Δ genotype did not associate with progression toward CKD stages 3 and 5 in our white population of patients with IgAN, although it did associate with a reduced level of glomerular immune deposits.
引用
- Jullien P, Laurent B, Claisse G, et al. Deletion Variants of CFHR1 and CFHR3 Associate with Mesangial Immune Deposits but Not with Progression of IgA Nephropathy. J Am Soc Nephrol. 2017. PMID: 29114042. doi:10.1681/ASN.2017010019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。